Integrated genomic analysis of survival outliers in glioblastoma

Sen Peng, Harshil Dhruv, Brock Armstrong, Bodour Salhia, Christophe Legendre, Jeffrey Kiefer, Julianna Parks, Selene Virk, Andrew E. Sloan, Quinn T. Ostrom, Jill S. Barnholtz-Sloan, Nhan Tran, Michael E. Berens

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background. To elucidate molecular features associated with disproportionate survival of glioblastoma (GB) patients, we conducted deep genomic comparative analysis of a cohort of patients receiving standard therapy (surgery plus concurrent radiation and temozolomide); "GB outliers" were identifed: long-term survivor of 33 months (LTS; n = 8) versus short-term survivor of 7 months (STS; n = 10). Methods. We implemented exome, RNA, whole genome sequencing, and DNA methylation for collection of deep genomic data from STS and LTS GB patients. Results. LTS GB showed frequent chromosomal gains in 4q12 (platelet derived growth factor receptor alpha and KIT) and 12q14.1 (cyclin-dependent kinase 4), and deletion in 19q13.33 (BAX, branched chain amino-acid transaminase 2, and cluster of differentiation 33). STS GB showed frequent deletion in 9p11.2 (forkhead box D4-like 2 and aquaporin 7 pseudogene 3) and 22q11.21 (Hypermethylated In Cancer 2). LTS GB showed 2-fold more frequent copy number deletions compared with STS GB. Gene expression differences showed the STS cohort with altered transcriptional regulators: activation of signal transducer and activator of transcription (STAT)5a/b, nuclear factor-kappaB (NF-?B), and interferon-gamma (IFNG), and inhibition of mitogen-activated protein kinase (MAPK1), extracellular signal-regulated kinase (ERK)1/2, and estrogen receptor (ESR)1. Expression-based biological concepts prominent in the STS cohort include metabolic processes, anaphase-promoting complex degradation, and immune processes associated with major histocompatibility complex class I antigen presentation; the LTS cohort features genes related to development, morphogenesis, and the mammalian target of rapamycin signaling pathway. Whole genome methylation analyses showed that a methylation signature of 89 probes distinctly separates LTS from STS GB tumors. Conclusion. We posit that genomic instability is associated with longer survival of GB (possibly with vulnerability to standard therapy); conversely, genomic and epigenetic signatures may identify patients where up-front entry into alternative, targeted regimens would be a preferred, more effcacious management.

Original languageEnglish (US)
Pages (from-to)833-844
Number of pages12
JournalNeuro-Oncology
Volume19
Issue number6
DOIs
StatePublished - 2017

Keywords

  • Genome sequencing
  • Glioblastoma
  • Outlier
  • Responders
  • Survival difference

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Integrated genomic analysis of survival outliers in glioblastoma'. Together they form a unique fingerprint.

  • Cite this

    Peng, S., Dhruv, H., Armstrong, B., Salhia, B., Legendre, C., Kiefer, J., Parks, J., Virk, S., Sloan, A. E., Ostrom, Q. T., Barnholtz-Sloan, J. S., Tran, N., & Berens, M. E. (2017). Integrated genomic analysis of survival outliers in glioblastoma. Neuro-Oncology, 19(6), 833-844. https://doi.org/10.1093/neuonc/now269